BSE Live
Nov 28, 16:01Prev. Close
1236.20
Open Price
1236.25
Bid Price (Qty.)
1215.45 (3)
Offer Price (Qty.)
1223.90 (38)
NSE Live
Nov 28, 15:57Prev. Close
1235.80
Open Price
1238.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1226.70 (1161)
| Key Financial Ratios of Aurobindo Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 59.81 | 54.16 | 32.90 | 45.19 | 91.05 | |
| Diluted EPS (Rs.) | 59.81 | 54.16 | 32.90 | 45.19 | 91.05 | |
| Cash EPS (Rs.) | 88.92 | 80.35 | 54.34 | 64.94 | 109.99 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 562.21 | 509.49 | 458.30 | 419.42 | 374.28 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 562.21 | 509.49 | 458.30 | 419.42 | 374.28 | |
| Revenue from Operations/Share (Rs.) | 546.21 | 495.00 | 424.23 | 400.33 | 422.85 | |
| PBDIT/Share (Rs.) | 124.05 | 109.24 | 68.43 | 80.34 | 97.53 | |
| PBIT/Share (Rs.) | 95.65 | 83.27 | 47.19 | 61.11 | 79.52 | |
| PBT/Share (Rs.) | 87.78 | 75.05 | 44.79 | 58.10 | 126.28 | |
| Net Profit/Share (Rs.) | 60.52 | 54.38 | 33.10 | 45.71 | 91.98 | |
| NP After MI And SOA / Share (Rs.) | 60.02 | 54.16 | 32.90 | 45.20 | 91.05 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 22.71 | 22.06 | 16.13 | 20.06 | 23.06 | |
| PBIT Margin (%) | 17.51 | 16.82 | 11.12 | 15.26 | 18.80 | |
| PBT Margin (%) | 16.06 | 15.16 | 10.55 | 14.51 | 29.86 | |
| Net Profit Margin (%) | 11.08 | 10.98 | 7.80 | 11.41 | 21.75 | |
| NP After MI And SOA Margin (%) | 10.98 | 10.94 | 7.75 | 11.29 | 21.53 | |
| Return on Networth/Equity (%) | 10.67 | 10.63 | 7.18 | 10.77 | 24.32 | |
| Return on Capital Employed (%) | 15.82 | 14.84 | 9.73 | 13.89 | 20.09 | |
| Return on Assets (%) | 7.00 | 7.03 | 4.83 | 7.80 | 15.75 | |
| Total Debt/Equity (X) | 0.24 | 0.21 | 0.18 | 0.10 | 0.23 | |
| Asset Turnover Ratio (%) | 0.67 | 0.68 | 0.67 | 0.69 | 0.79 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.85 | 1.98 | 1.87 | 2.22 | 1.86 | |
| Quick Ratio (X) | 1.13 | 1.18 | 1.13 | 1.30 | 1.01 | |
| Inventory Turnover Ratio (X) | 3.12 | 1.18 | 1.20 | 0.89 | 0.99 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 22.79 | 9.95 | 4.39 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 13.85 | 6.98 | 3.66 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 77.21 | 90.05 | 95.61 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 86.15 | 93.02 | 96.34 | |
| Coverage Ratios | ||||||
| Interest Coverage Ratios (%) | 15.76 | 22.09 | 28.54 | 96.77 | 76.71 | |
| Interest Coverage Ratios (Post Tax) (%) | 15.76 | 22.09 | 28.54 | 96.77 | 76.71 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 67,055.18 | 63,875.80 | 29,138.94 | 37,374.61 | 51,145.96 | |
| EV/Net Operating Revenue (X) | 2.11 | 2.20 | 1.17 | 1.59 | 2.06 | |
| EV/EBITDA (X) | 9.31 | 9.98 | 7.27 | 7.94 | 8.95 | |
| MarketCap/Net Operating Revenue (X) | 2.12 | 2.20 | 1.22 | 1.67 | 2.08 | |
| Retention Ratios (%) | 0.00 | 0.00 | 77.20 | 90.04 | 95.60 | |
| Price/BV (X) | 2.06 | 2.14 | 1.13 | 1.59 | 2.36 | |
| Price/Net Operating Revenue | 2.12 | 2.20 | 1.22 | 1.67 | 2.08 | |
| Earnings Yield | 0.05 | 0.05 | 0.06 | 0.07 | 0.10 |
23.11.2025
Aurobindo Pharma incurring loss at China Plant; hopes to achieve break-even by Q4
14.11.2025
12.11.2025
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL